MiMedx Group Inc (MDXG)vsMerck & Company Inc (MRK)
MDXG
MiMedx Group Inc
$3.36
+8.91%
HEALTHCARE · Cap: $458.33M
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 15429% more annual revenue ($65.01B vs $418.63M). MRK leads profitability with a 28.1% profit margin vs 11.6%. MDXG appears more attractively valued with a PEG of 2.88. MDXG earns a higher WallStSmart Score of 74/100 (B).
MDXG
Strong Buy74
out of 100
Grade: B
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MDXG.
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Earnings expanding 99.5% YoY
Every $100 of equity generates 22 in profit
Reasonable price relative to book value
Revenue surging 27.1% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Expensive relative to growth rate
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : MDXG
The strongest argument for MDXG centers on P/E Ratio, EPS Growth, Return on Equity. Revenue growth of 27.1% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : MDXG
The primary concerns for MDXG are Market Cap, PEG Ratio.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
MDXG profiles as a growth stock while MRK is a value play — different risk/reward profiles.
MDXG carries more volatility with a beta of 1.65 — expect wider price swings.
MDXG is growing revenue faster at 27.1% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MDXG scores higher overall (74/100 vs 59/100) and 27.1% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MiMedx Group Inc
HEALTHCARE · BIOTECHNOLOGY · USA
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?